InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.00%
)
US TECH 100
19,490.40
(
-0.03%
)
Dow Jones
42,052.19
(
0.00%
)
Brent Oil
74.82
(
1.00%
)
Bitcoin
68,596.63
(
-0.21%
)
Post# of 253518
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120661
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 94805

Tuesday, 04/27/2010 2:11:03 AM

Tuesday, April 27, 2010 2:11:03 AM

Post# of 253518

Upon the April, 2008 expiration of the 30-month Hatch-Waxman stay, the prior FDA tentative approval of [Aricept] ANDAs could then be made a final approval.

Correct, but that 30-month stay pertained to a different patent. Why didn’t the FDA require the ANDA filers to make a Paragraph-IV certification on Eisai’s 4895841 patent?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up